Carmell Co. (NASDAQ:CTCX) Sees Large Growth in Short Interest

Carmell Co. (NASDAQ:CTCX) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 391,200 shares, a growth of 968.9% from the September 30th total of 36,600 shares. Based on an average daily volume of 4,500,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.9% of the company’s shares are short sold.

Hedge Funds Weigh In On Carmell

A hedge fund recently bought a new stake in Carmell stock. Hubbell Strickland Wealth Management LLC purchased a new position in shares of Carmell Co. (NASDAQ:CTCX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,548 shares of the company’s stock, valued at approximately $32,000. Hubbell Strickland Wealth Management LLC owned approximately 0.07% of Carmell as of its most recent SEC filing. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Carmell Stock Performance

Carmell stock traded up $0.02 during trading hours on Friday, reaching $0.37. 464,345 shares of the company’s stock traded hands, compared to its average volume of 1,467,069. Carmell has a fifty-two week low of $0.29 and a fifty-two week high of $4.31. The firm’s 50 day moving average is $0.49 and its 200-day moving average is $1.37.

Carmell (NASDAQ:CTCX) last issued its earnings results on Wednesday, August 14th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million for the quarter.

Carmell Company Profile

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.